Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Enasidenib in IDH2-mutated myelodysplastic syndrome
2018-001693-25Phase 2Active
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of enasidenib in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (3 cohorts), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Overall hematological response at 3 months (cohorts A and B), Overall hematological response at 6 months (cohorts A and B) and 1 more. Started Sep 2018; status: active.
02
Drugs
enasidenib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-001693-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001693-25.